Propanc Biopharma, Inc. (PPCB): Capital Expenditures
$4.9K
Year ended 2026-06-30
-6.7%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $4.9K | n/a | 2026-09-25, From 2025-07-01 |
| No annual figure between 2019-06-30 and 2026-06-30. | |||
| 2019-06-30 | $2.9K | n/a | 2020-10-01, From 2018-07-01 |
| No annual figure between 2016-06-30 and 2019-06-30. | |||
| 2016-06-30 | $9.9K | +153.2% | 2017-09-28, From 2015-07-01 |
| 2015-06-30 | $3.9K | n/a | 2016-09-28, From 2014-07-01 |
| 2014-06-30 | $0 | n/a | 2015-09-30, From 2013-07-01 |
| No annual figure between 2011-06-30 and 2014-06-30. | |||
| 2011-06-30 | $3.5K | n/a | 2012-10-15, From 2010-07-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | 2026-06-30 | $4.9K | n/a |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $442.3K | n/m |
| Imunon, Inc. (IMNN) | 2025-12-31 | $280.6K | +849.8% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $28.0K | +250.0% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $2.0K | -84.6% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $3.0K | n/a |
| Exicure, Inc. (XCUR) | 2025-12-31 | $1.0K | n/a |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $8.0K | +33.3% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $2.0K | -75.0% |
Compare PPCB, ELAB, IMNN, CALC side by side · Screen every company in Pharmaceutical Preparations ↗